Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).

  • FEAnalytics.com
  • FEInvest.net
  • FETransmission.com
  • Investegate.co.uk
  • Trustnet.hk
  • Trustnetoffshore.com
  • Trustnetmiddleeast.com

For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.

WHAT INFORMATION DO WE COLLECT ABOUT YOU?

We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.

COOKIES

In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.

HOW WE USE INFORMATION

We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.

ACCESS TO YOUR INFORMATION AND CORRECTION

We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.

WHERE WE STORE YOUR PERSONAL DATA

The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.

CHANGES TO OUR PRIVACY POLICY

Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.

OTHER WEBSITES

Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.

CONTACT

If you want more information or have any questions or comments relating to our privacy policy please email publishing@financialexpress.net in the first instance.

 Information  X 
Enter a valid email address

ProStrakan Group plc (PSK)

  Print      Mail a friend       Annual reports

Thursday 25 June, 2009

ProStrakan Group plc

Product Update

RNS Number : 4698U
ProStrakan Group plc
25 June 2009
 



ProStrakan Group plc 



ProStrakan Announces Publication of 

Notice of Allowance for Sancuso US Patent 


Galashiels, Scotland, 25th June, 2009 - ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today announces that the United States Patent and Trademark Office has published a Notice of Allowance for the US Patent for Sancuso, ProStrakan's transdermal granisetron patch. 


Consequently, subject to the payment by ProStrakan of the appropriate issue fee, a full US Patent for Sancuso is expected to be formally issued shortly.  ProStrakan has also been granted Patent Term Adjustment which provides for the Company to receive an extension to the life of the Patent by a further 373 days until 2025. 


Sancuso is a transdermal patch that delivers granisetron, an established 5-HT3 receptor antagonist, steadily into the bloodstream for up to seven days, helping to prevent the side-effects of nausea and vomiting in patients undergoing chemotherapy for up to five consecutive days, without the need for daily injections or having to swallow pills.  


Sancuso received marketing authorisation from the US Food and Drug Administration in September 2008 and was launched in November 2008.  


Commenting on the publication of the Notice of Allowance, ProStrakan's Chief Executive, Dr Wilson Totten, said:


"Today's announcement, signalling the imminent grant of a US Patent for Sancuso, represents a critically important achievement for the long term, protecting one of our key new drugs in the US, the world's largest pharmaceutical market.  Sancuso is already the subject of granted patents in the EU and Japan.

 

"It is an important part of our strategy to move the business progressively into well differentiated, well protected products with clear patient benefits. The Notice of Allowance for the US Patent is a key element in delivering this."


For more information on this announcement, please contact:


ProStrakan Corporate

+44 (0)1896 664000

Dr Wilson Totten, Chief Executive


Paul Garvey, CFO

Callum Spreng, Corporate Communications 




Financial Dynamics

+44 (0)20 7831 3113

Ben Brewerton




Trout Group (for US investor enquiries)


Gitanjali Jain

+1 (646) 378-2949



ProStrakan


ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. 

 

ProStrakan's head office is situated in Galashiels in Scotland. The company’s development capabilities are centred on Galashiels and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain and other EU countries. www.prostrakan.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PRLIFFELRRISFIA